MAP2K7 and breast cancer: It is noteworthy that although 100 nM MEK inhibitor PD0325901 effectively eradicated ERK activity in breast cancer cells (Supplementary Fig. 9a, b), such dose or higher exhibited marginal efficacy in restraining MDA-MB-231 and SUM159PT cell proliferation (Supplementary Fig. 8d, f).